Gotowa bibliografia na temat „Methotrexate Toxicology”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Methotrexate Toxicology”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Methotrexate Toxicology"
Slørdal, L., R. Jaeger, J. Kjaeve i J. Aarbakke. "Pharmacokinetics of 7-Hydroxy-methotrexate and Methotrexate in the Rat". Pharmacology & Toxicology 63, nr 2 (sierpień 1988): 81–84. http://dx.doi.org/10.1111/j.1600-0773.1988.tb00915.x.
Pełny tekst źródłaUNDP/UNFPA/WHO/World Bank Special P. "Methotrexate for the termination of early pregnancy: a toxicology review". Reproductive Health Matters 5, nr 9 (styczeń 1997): 162–67. http://dx.doi.org/10.1016/s0968-8080(97)90020-3.
Pełny tekst źródłaArmagan, A., E. Uzar, E. Uz, HR Yilmaz, S. Kutluhan, HR Koyuncuoglu, S. Soyupek, H. Cam i TA Serel. "Caffeic acid phenethyl ester modulates methotrexate-induced oxidative stress in testes of rat". Human & Experimental Toxicology 27, nr 7 (lipiec 2008): 547–52. http://dx.doi.org/10.1177/0960327108092293.
Pełny tekst źródłaBardin, Philip G., David J. Fraenkel i Richard W. Beasley. "Methotrexate in Asthma". Drug Safety 9, nr 3 (wrzesień 1993): 151–55. http://dx.doi.org/10.2165/00002018-199309030-00002.
Pełny tekst źródłaGökçe, Ahmet, Suleyman Oktar, Ahmet Koc i Zafer Yonden. "Protective effects of thymoquinone against methotrexate-induced testicular injury". Human & Experimental Toxicology 30, nr 8 (2.09.2010): 897–903. http://dx.doi.org/10.1177/0960327110382564.
Pełny tekst źródłaRoy(Pal), Madhumita, Sharmila Sengupta, Rita Ghosh, Nitao P. Bhattacharyya, Subrata K. Dey i Sukhendu B. Bhattacharjee. "Characterisation of methotrexate-resistant clones". Mutation Research/Environmental Mutagenesis and Related Subjects 291, nr 1 (luty 1993): 43–51. http://dx.doi.org/10.1016/0165-1161(93)90016-s.
Pełny tekst źródłaAngelova, E., M. Krsnik-Rasol, M. Biruš i D. Papeš. "Methotrexate effects on plant cells". Mutation Research/Environmental Mutagenesis and Related Subjects 271, nr 2 (1992): 148. http://dx.doi.org/10.1016/0165-1161(92)91162-k.
Pełny tekst źródłaRaveendran, R., W. Heybroek, M. Caulfield, M. Lawson, S. M. L. Abrams, P. F. M. Wrigley, M. Slevin i P. Turner. "Indomethacin and Protein Binding of Methotrexate". Human & Experimental Toxicology 11, nr 4 (lipiec 1992): 291–93. http://dx.doi.org/10.1177/096032719201100411.
Pełny tekst źródłaLoVecchio, Frank, Kenneth D. Katz, David J. Watts i Ian O. Wood. "Four-year experience with methotrexate exposures". Journal of Medical Toxicology 4, nr 3 (wrzesień 2008): 149–50. http://dx.doi.org/10.1007/bf03161192.
Pełny tekst źródłaStockley, Ivan H. "Methotrexate—NSAID interactions". Drug Intelligence & Clinical Pharmacy 21, nr 6 (czerwiec 1987): 546. http://dx.doi.org/10.1177/106002808702100617.
Pełny tekst źródłaRozprawy doktorskie na temat "Methotrexate Toxicology"
Tran, Thi Tuyet Mai. "Toxicologie du méthotrexate". Paris 5, 1993. http://www.theses.fr/1993PA05P200.
Pełny tekst źródłaMuhrez, Kienana. "La métabolomique urinaire permet-elle d'identifier des biomarqueurs visant à optimiser l'utilisation des médicaments anticancéreux ?" Thesis, Tours, 2017. http://www.theses.fr/2017TOUR3303/document.
Pełny tekst źródłaMTX is an anticancer agent used at high doses for the treatment of malignant haemopathies and some solid tumors. It presents an important pharmacokinetic variability (PK), manifested by overexposures causing very severe toxicities, especially when administered at high doses. Delayed elimination of MTX still occurs unexpectedly and there is currently no biomarker that allows early diagnosis of the risk of overexposure. Our work focused on the determinants of renal elimination of MTX, and particularly on the role of MRP2 / ABCC2 in this process. This work is therefore devoted to (1) the search for metabolomic biomarkers predictive of MTX PK and (2) the identification of endogenous substrates of MRP2, from a panel of 217 urinary organic acids analyzed by gas chromatography-mass spectrometry. Our analyses resulted in a profile of 28 endogenous organic anions, predictive of CL MTX. The tool was, on the other hand, poorly adapted to the prediction of delayed elimination. For the second part, our results tend to show that 8 urinary metabolites are potential biomarkers of MRP2 activity. Their clinical use still requires confirmatory studies
Moya, Alvarado Patricia. "Estudios farmacogenéticos del metotrexato en la artritis reumatoide". Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/384724.
Pełny tekst źródłaMethotrexate (MTX) is the first-line treatment option for rheumatoid arthritis (RA) patients. Recently, the interest of identifying biomarkers that can predict the efficacy and toxicity of MTX has been grown. Polymorphisms (SNPs, Single Nucleotide Polymorphism) in genes involved directly or indirectly in the metabolic pathway of MTX and in the transport and activation (polyglutamation) of MTX inside the cell can be predictors of response and toxicity of MTX. The objective of this study is to evaluate the usefulness of different pharmacogenetics markers in relation to the response and / or toxicity of rheumatoid arthritis patients treated with MTX in monotherapy. The investigation has been divided into two parts. The first part is based on the study of 27 polymorphisms of 5 genes that are involved with the mechanism of action of MTX (DHFR, TYMS, MTHFR, ATIC and CCND1). The second part is based on the study of 34 polymorphisms of 4 genes involved in the cellular transport of MTX and in its activation and inactivation through polyglutamation (SLC19A1 / RFC1, ABCB1, FPGS and GGH). Regarding genes involved in the mechanism of MTX’ action the results show an association between three SNPs and the response to treatment with MTX in patients with rheumatoid arthritis. The involved SNPs are rs17421511 and rs1476413 of MTHFR gene and the SNP rs1643650 of the DHFR gene. Besides, the two SNPs rs16853826 and rs10197559 of ATIC gene are associated with toxicity. Concerning genes involved in cellular transport of MTX and in their activation/inactivation through polyglutamation the results obtained in this study show an association between two SNPs and the treatment response of MTX. In this case, the involved SNPs are rs10987742 and rs10106 of FPGS gene. The SNP rs10106 is also associated with the presence of adverse events and the survival time of the drug. The results also show that three SNPs rs868755, rs10280623 and rs1858923 of ABCB1 gene are associated with MTX toxicity; and two SNPs rs868755 and rs10264990 of the same gene are also associated with the survival time of MTX. In conclusion, certain genetic variants in genes involved in the metabolic pathway of MTX and in its transportation and cellular activation could be considered as pharmacogenetics markers for response and toxicity in rheumatoid arthritis’ patients treated with MTX in monotherapy.
Dodridge, M. E. (Miles Edward). "The effects of variable dose methotrexate infusion in the laboratory rat". 1987. http://web4.library.adelaide.edu.au/theses/09DM/09dmd641.pdf.
Pełny tekst źródłaCzęści książek na temat "Methotrexate Toxicology"
Bentur, Yedidia, i Yael Lurie. "Methotrexate". W Critical Care Toxicology, 1171–218. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-17900-1_109.
Pełny tekst źródłaBentur, Yedidia, i Yael Lurie. "Methotrexate". W Critical Care Toxicology, 1–49. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-20790-2_109-1.
Pełny tekst źródłaMolinelli, Alejandro R., i Kristine R. Crews. "Methotrexate toxicity—case study". W Toxicology Cases for the Clinical and Forensic Laboratory, 157–60. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-12-815846-3.00044-2.
Pełny tekst źródłaYang, Yifei, i Kiang-Teck J. Yeo. "Different cross-reactivity profiles of methotrexate immunoassays and the clinical management of methotrexate treatment". W Toxicology Cases for the Clinical and Forensic Laboratory, 165–67. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-12-815846-3.00046-6.
Pełny tekst źródłaBhatt, Valkal, Michael Scordo i Dean C. Carlow. "Case study—methotrexate toxicity, treatment, and measurement". W Toxicology Cases for the Clinical and Forensic Laboratory, 151–56. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-12-815846-3.00043-0.
Pełny tekst źródłaWu, Fang, Andrew W. Lyon i Martha E. Lyon. "The importance of selecting an appropriate method for measuring methotrexate concentration after glucarpidase rescue: immunoassay or LC–MS/MS?" W Toxicology Cases for the Clinical and Forensic Laboratory, 161–63. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-12-815846-3.00045-4.
Pełny tekst źródłaNegrei, Carolina, i Daniel Boda. "The Role of Methotrexate in Psoriatic Therapy in the Age of Biologic and Biosimilar Medication: Therapeutic Benefits versus Toxicology Emergencies". W An Interdisciplinary Approach to Psoriasis. InTech, 2017. http://dx.doi.org/10.5772/67793.
Pełny tekst źródła